Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · IEX Real-Time Price · USD
67.49
+0.49 (0.73%)
May 20, 2024, 1:51 PM EDT - Market open
Viking Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Viking Therapeutics stock have an average target of 103.44, with a low estimate of 32 and a high estimate of 138. The average target predicts an increase of 53.27% from the current stock price of 67.49.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for VKTX stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 10 | 8 | 8 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 12 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy → Strong Buy Upgrades $115 → $116 | Buy → Strong Buy | Upgrades | $115 → $116 | +71.88% | May 16, 2024 |
| Truist Securities | Truist Securities | Strong Buy Reiterates $120 | Strong Buy | Reiterates | $120 | +77.80% | May 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +33.35% | Apr 25, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $116 → $138 | Buy | Maintains | $116 → $138 | +104.47% | Mar 27, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $116 → $138 | Buy | Maintains | $116 → $138 | +104.47% | Mar 26, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.15
from -0.91
EPS Next Year
-1.55
from -1.15
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 200.7M | 491.4M | 1.1B |
| Avg | n/a | n/a | 30.9M | 127.5M | 480.8M |
| Low | n/a | n/a | n/a | n/a | 57.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 1,487.9% | 781.9% |
| Avg | - | - | - | 311.9% | 277.2% |
| Low | - | - | - | - | -54.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.86 | -1.20 | -0.26 | 2.27 | 7.46 |
| Avg | -1.15 | -1.55 | -1.53 | -0.63 | 2.17 |
| Low | -1.50 | -2.21 | -2.52 | -3.39 | -1.17 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.